Pliant Therapeutics Announces Positive Safety and

Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns...

Related Keywords

United States ,Toronto ,Ontario ,Canada ,Gideon Hirshfield ,Christopher Keenan ,Clin Gastroenterol Hepatol ,Terry Horner ,Krisv Kowdley ,University Of Toronto ,Corporate Communications ,Linkedin ,Liver Institute ,Clinical Development Next ,Nasdaq ,Drug Administration ,European Medicines Agency ,Pliant Therapeutics Inc ,Facebook ,Youtube ,Enhanced Liver Fibrosis ,Chief Medical Officer ,Well Tolerated ,Serious Adverse ,Mayo Score ,Demonstrated Antifibrotic Activity ,Suspected Moderate ,Severe Liver Fibrosis ,Itch Numerical Rating Scale ,Liver Institute Northwest ,Washington State ,Development Next ,Primary Sclerosing ,Terry Horner Chair ,Autoimmune Liver Disease ,Pliant Therapeutics ,Fast Track Designation ,Orphan Drug Designation ,Private Securities Litigation Reform Act ,Financial Condition ,Quarterly Report ,Media Contact ,Investor Relations ,Magn Reson ,Nasdaq Plrx ,Nc ,